Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trials
Antonios Bayas(University of Augsburg), Sven G. Meuth(University Hospital Münster), Refik Pul, Thomas Skripuletz(Medizinische Hochschule Hannover), Monika Christ(University of Augsburg), Simon Faissner(St. Josef-Hospital), Juliane Klehmet(Jüdisches Krankenhaus Berlin)
Cited by 25
Related Papers
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
|Nature Reviews Drug Discovery|2019|456
Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells
|Nature Communications|2016|122
Multi-target-directed phenol–triazole ligands as therapeutic agents for Alzheimer's disease
|Chemical Science|2017|93